Ipamorelin vs CJC-1295: Comparing Two Growth Hormone Secretagogues in Research
A side-by-side research overview of Ipamorelin and CJC-1295 (NO DAC). Covers mechanism, receptor selectivity, half-life, and why preclinical studies frequently pair the two.
For in-vitro and laboratory research only. PrimeHelix Labz does not provide medical, clinical, or dosing guidance for any compound discussed below.
Ipamorelin and CJC-1295 are two of the most-studied research peptides in the growth-hormone secretagogue category. They are often discussed together because they act on different receptors, with mechanisms reported to be complementary in published rodent studies. This article walks through how they differ and why preclinical protocols frequently evaluate them in parallel.
What each molecule is
Ipamorelin
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), the ghrelin receptor. Published animal studies report that Ipamorelin stimulates pulsatile GH release without significant elevation of cortisol, prolactin, or ACTH — a selectivity that has made it a recurring research tool for isolating GH-axis effects. Available as Ipamorelin 5mg and Ipamorelin 10mg lyophilized.
CJC-1295 (NO DAC)
CJC-1295 without the Drug Affinity Complex modification is a 30–amino-acid synthetic analog of growth hormone-releasing hormone (GHRH). Unlike its DAC-modified counterpart, CJC-1295 NO DAC has a short half-life — typically reported at ~30 minutes in published pharmacokinetic work. It acts on the GHRH receptor in the anterior pituitary. Available as CJC-1295 5mg and CJC-1295 10mg.
Why they appear together in protocols
The two molecules target different upstream receptors that converge on somatotroph GH release:
- CJC-1295 activates the GHRH receptor.
- Ipamorelin activates the ghrelin / GHSR-1a receptor.
Published preclinical literature reports synergistic GH release when both pathways are stimulated simultaneously, larger than the sum of either alone. This is why research-supply catalogs commonly offer the pre-combined CJC(NO DAC)/IPA 5mg/5mg stack for parallel-pathway studies.
Side-by-side
| Attribute | Ipamorelin | CJC-1295 (NO DAC) |
|---|---|---|
| Receptor | GHSR-1a (ghrelin) | GHRH receptor |
| Length | 5 amino acids | 30 amino acids |
| Half-life (reported) | ~2 hours | ~30 minutes |
| Off-target hormone effects | Minimal (selective) | Minimal at normal research doses |
| Common research use | GH-axis isolation studies | GHRH-axis isolation; pulse-amplitude studies |
Handling and storage
Both peptides ship as lyophilized white powder and follow standard peptide storage protocols. See our peptide storage guide for shelf life by storage condition. Both are typically reconstituted in bacteriostatic water for research workflows.
What to confirm on the COA
- Sequence — for Ipamorelin, the Aib-His-D-2-Nal-D-Phe-Lys-NH2 sequence; for CJC-1295, confirm the absence of the DAC modification if NO-DAC is required.
- Purity — ≥98% HPLC is standard.
- Mass spec match for the expected molecular weight.
For a deeper walkthrough see how to read a peptide COA.
Further reading
For broader context on growth-hormone secretagogue research, see our overviews of Sermorelin vs Tesamorelin vs CJC-1295 and the BPC-157 research guide.
Reminder: All content is summarized from preclinical literature for laboratory use only. Products are not intended for human consumption.